Symbols / REVB
REVB Chart
About
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.54M |
| Enterprise Value | -10.71M | Income | -14.08M | Sales | — |
| Book/sh | 12.27 | Cash/sh | 8.58 | Dividend Yield | — |
| Payout | 0.00% | Employees | 8 | IPO | — |
| P/E | 0.00 | Forward P/E | -0.10 | PEG | — |
| P/S | — | P/B | 0.11 | P/C | — |
| EV/EBITDA | 1.30 | EV/Sales | — | Quick Ratio | 6.85 |
| Current Ratio | 6.92 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 325.00 | EPS next Y | -13.66 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-05 | ROA | -52.64% |
| ROE | -118.88% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 2.62M |
| Shs Float | 1.42M | Short Float | 10.70% | Short Ratio | 0.17 |
| Short Interest | — | 52W High | 52.06 | 52W Low | 1.33 |
| Beta | -0.13 | Avg Volume | 647.54K | Volume | 57.99K |
| Target Price | $85.00 | Recom | None | Prev Close | $1.39 |
| Price | $1.35 | Change | -2.88% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$85.00
Mean price target
2. Current target
$1.33
Latest analyst target
3. DCF / Fair value
$-48.26
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.33
Low
$80.00
High
$90.00
Mean
$85.00
- Revelation Biosciences trades new 5-year warrants for $11M cash - Stock Titan Fri, 23 Jan 2026 08
- REVB Stock Drops 10% After Company Announces Third Reverse Split In A Year - Stocktwits Mon, 26 Jan 2026 08
- Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours? - Benzinga Fri, 23 Jan 2026 08
- Revelation Biosciences to combine 4 shares into 1 for Nasdaq bid - Stock Titan Mon, 26 Jan 2026 08
- Revelation Biosciences (REVB) Price Target Increased by 300.00% to 86.70 - Nasdaq Wed, 04 Feb 2026 08
- Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering - Yahoo Finance hu, 29 May 2025 07
- Revelation Biosciences (REVB) stock ticks up premarket after FDA lays out Gemini trial path - TechStock² Fri, 23 Jan 2026 08
- Revolution Beauty Updates Market on LTIP Block Listing Activity - The Globe and Mail Wed, 04 Feb 2026 08
- REVB stock touches 52-week low at $0.86 amid sharp annual decline - Investing.com hu, 29 May 2025 07
- Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025 - Business Wire ue, 01 Jul 2025 07
- Revelation Biosciences extends stock warrants expiration - MSN Wed, 03 Dec 2025 08
- Revelation Biosciences Raises Capital via Warrant Inducement - TipRanks hu, 29 Jan 2026 08
- Revelation Biosciences Stock Slides 17% After Company Reports 3 Severe Adverse Events In Early Stage Trial Of Inflammation Drug - Stocktwits ue, 09 Sep 2025 07
- FDA, Revelation map single trial for deadly kidney injury drug - Stock Titan Wed, 21 Jan 2026 08
- Revelation Biosciences submits end-of-phase 1 package to FDA - Investing.com hu, 20 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 41981 | 37783 | — | Stock Award(Grant) at price 0.90 per share. | CHAWLA LAKHMIR S | Director | — | 2026-01-08 00:00:00 | D |
| 1 | 41981 | 37783 | — | Stock Award(Grant) at price 0.90 per share. | CARVER JENNIFER A | Director | — | 2026-01-08 00:00:00 | D |
| 2 | 532829 | 479546 | — | Stock Award(Grant) at price 0.90 per share. | ROLKE JAMES M | Chief Executive Officer | — | 2026-01-08 00:00:00 | D |
| 3 | 78145 | 70330 | — | Stock Award(Grant) at price 0.90 per share. | ZYGMONT CHESTER STANLEY III | Chief Financial Officer | — | 2026-01-08 00:00:00 | I |
| 4 | 41981 | 37783 | — | Stock Award(Grant) at price 0.90 per share. | ROPER JESS | Director | — | 2026-01-08 00:00:00 | D |
| 5 | 15625 | 20000 | — | Stock Award(Grant) at price 1.28 per share. | CHAWLA LAKHMIR S | Director | — | 2025-10-29 00:00:00 | D |
| 6 | 15625 | 20000 | — | Stock Award(Grant) at price 1.28 per share. | CARVER JENNIFER A | Director | — | 2025-10-29 00:00:00 | D |
| 7 | 390614 | 499986 | — | Stock Award(Grant) at price 1.28 per share. | ROLKE JAMES M | Chief Executive Officer | — | 2025-10-29 00:00:00 | D |
| 8 | 390614 | 499986 | — | Stock Award(Grant) at price 1.28 per share. | ZYGMONT CHESTER STANLEY III | Chief Financial Officer | — | 2025-10-29 00:00:00 | I |
| 9 | 15625 | 20000 | — | Stock Award(Grant) at price 1.28 per share. | ROPER JESS | Director | — | 2025-10-29 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -8.03M | -16.96M | -10.84M | -11.93M |
| TotalUnusualItems | 81.44K | 8.33M | ||
| TotalUnusualItemsExcludingGoodwill | 81.44K | 8.33M | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -15.04M | -120.25K | -10.83M | -11.99M |
| ReconciledDepreciation | 27.92K | 25.05K | 25.05K | 16.78K |
| EBITDA | -7.95M | -8.63M | -10.84M | -11.93M |
| EBIT | -7.98M | -8.66M | -10.86M | -11.95M |
| NormalizedIncome | -15.12M | -8.45M | -10.83M | -11.99M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -15.04M | -120.25K | -10.83M | -11.99M |
| TotalExpenses | 7.98M | 8.66M | 10.86M | 11.95M |
| TotalOperatingIncomeAsReported | -7.98M | -8.66M | -10.86M | -11.95M |
| DilutedAverageShares | 14.29K | 1.19K | 118.00 | 64.00 |
| BasicAverageShares | 14.29K | 1.19K | 118.00 | 64.00 |
| DilutedEPS | -1.05K | -101.28 | -91.78K | -187.29K |
| BasicEPS | -1.05K | -101.28 | -91.78K | -187.29K |
| DilutedNIAvailtoComStockholders | -15.04M | -120.25K | -10.83M | -11.99M |
| NetIncomeCommonStockholders | -15.04M | -120.25K | -10.83M | -11.99M |
| NetIncome | -15.04M | -120.25K | -10.83M | -11.99M |
| NetIncomeIncludingNoncontrollingInterests | -15.04M | -120.25K | -10.83M | -11.99M |
| NetIncomeContinuousOperations | -15.04M | -120.25K | -10.83M | -11.99M |
| PretaxIncome | -15.04M | -120.25K | -10.83M | -11.99M |
| OtherIncomeExpense | -7.06M | 8.54M | 34.96K | -36.35K |
| OtherNonOperatingIncomeExpenses | -7.14M | 207.47K | 34.96K | -36.35K |
| GainOnSaleOfSecurity | 81.44K | 8.33M | ||
| OperatingIncome | -7.98M | -8.66M | -10.86M | -11.95M |
| OperatingExpense | 7.98M | 8.66M | 10.86M | 11.95M |
| ResearchAndDevelopment | 3.55M | 4.15M | 5.38M | 6.91M |
| SellingGeneralAndAdministration | 4.43M | 4.51M | 5.49M | 5.04M |
| GeneralAndAdministrativeExpense | 4.43M | 4.51M | 5.49M | 5.04M |
| OtherGandA | 1.66M | 2.24M | 3.61M | 2.47M |
| SalariesAndWages | 2.77M | 2.27M | 1.87M | 2.56M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 43.52K | 1.38K | 118.00 | 64.00 |
| ShareIssued | 43.52K | 1.38K | 118.00 | 64.00 |
| TotalDebt | 0.00 | 16.75K | ||
| TangibleBookValue | 4.71M | 6.65M | 1.05M | -99.47K |
| InvestedCapital | 4.71M | 6.65M | 1.05M | -99.47K |
| WorkingCapital | 4.65M | 6.58M | 962.32K | -229.61K |
| NetTangibleAssets | 4.71M | 6.65M | 1.05M | -99.47K |
| CapitalLeaseObligations | 0.00 | 16.75K | ||
| CommonStockEquity | 4.71M | 6.65M | 1.05M | -99.47K |
| PreferredStockEquity | 7.48M | |||
| TotalCapitalization | 4.71M | 6.65M | 1.05M | -99.47K |
| TotalEquityGrossMinorityInterest | 4.71M | 6.65M | 1.05M | -99.47K |
| StockholdersEquity | 4.71M | 6.65M | 1.05M | -99.47K |
| RetainedEarnings | -40.51M | -25.47M | -25.35M | -14.52M |
| AdditionalPaidInCapital | 45.21M | 32.11M | 26.40M | 14.42M |
| CapitalStock | 522.00 | 16.00 | 77.00 | 282.00 |
| CommonStock | 522.00 | 16.00 | 77.00 | 282.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 1.91M | 5.56M | 4.45M | 2.14M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 1.91M | 5.56M | 4.45M | 2.14M |
| OtherCurrentLiabilities | 2.25K | 141.28K | ||
| CurrentDeferredLiabilities | 0.00 | 2.91M | 2.91M | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 16.75K | |||
| CurrentCapitalLeaseObligation | 0.00 | 16.75K | ||
| PayablesAndAccruedExpenses | 1.91M | 2.51M | 1.54M | 2.12M |
| CurrentAccruedExpenses | 1.13M | 1.15M | 985.50K | 1.53M |
| Payables | 783.62K | 1.36M | 554.21K | 596.26K |
| AccountsPayable | 783.62K | 1.36M | 554.21K | 596.26K |
| TotalAssets | 6.62M | 12.21M | 5.50M | 2.04M |
| TotalNonCurrentAssets | 56.33K | 65.08K | 90.13K | 130.14K |
| NetPPE | 56.33K | 65.08K | 90.13K | 130.14K |
| AccumulatedDepreciation | -94.80K | -66.88K | -41.83K | -16.78K |
| GrossPPE | 151.13K | 131.96K | 131.96K | 146.92K |
| OtherProperties | 151.13K | 131.96K | 131.96K | 146.92K |
| CurrentAssets | 6.57M | 12.15M | 5.41M | 1.91M |
| OtherCurrentAssets | 49.50K | 29.48K | 73.13K | 148.73K |
| CurrentDeferredAssets | 0.00 | 71.13K | 87.17K | 0.00 |
| PrepaidAssets | 17.20K | 55.22K | 0.00 | 488.61K |
| CashCashEquivalentsAndShortTermInvestments | 6.50M | 11.99M | 5.25M | 1.27M |
| CashAndCashEquivalents | 6.50M | 11.99M | 5.25M | 1.27M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -18.34M | -7.29M | -11.22M | -11.22M |
| RepurchaseOfCapitalStock | 0.00 | -5.00K | ||
| RepaymentOfDebt | 0.00 | -3.30M | 0.00 | |
| IssuanceOfDebt | 0.00 | 2.50M | 0.00 | |
| IssuanceOfCapitalStock | 5.42M | 14.03M | 4.46M | 8.00M |
| CapitalExpenditure | -19.17K | -131.96K | ||
| EndCashPosition | 6.50M | 11.99M | 5.25M | 1.27M |
| BeginningCashPosition | 11.99M | 5.25M | 1.27M | 4.49M |
| ChangesInCash | -5.49M | 6.74M | 3.98M | -3.22M |
| FinancingCashFlow | 12.85M | 14.03M | 15.20M | 8.00M |
| CashFlowFromContinuingFinancingActivities | 12.85M | 14.03M | 15.20M | 8.00M |
| NetOtherFinancingCharges | 11.53M | |||
| ProceedsFromStockOptionExercised | 7.43M | 34.00 | 5.09K | 0.00 |
| NetPreferredStockIssuance | 0.00 | -5.00K | 5.00K | 7.40M |
| PreferredStockPayments | 0.00 | -5.00K | ||
| PreferredStockIssuance | 5.00K | 7.40M | ||
| NetCommonStockIssuance | 5.42M | 14.03M | 4.45M | 600.00K |
| CommonStockIssuance | 5.42M | 14.03M | 4.45M | 600.00K |
| NetIssuancePaymentsOfDebt | 0.00 | -796.88K | 0.00 | |
| NetShortTermDebtIssuance | 0.00 | -796.88K | 0.00 | |
| ShortTermDebtPayments | 0.00 | -3.30M | 0.00 | |
| ShortTermDebtIssuance | 0.00 | 2.50M | 0.00 | |
| InvestingCashFlow | -19.17K | 0.00 | 0.00 | -131.96K |
| CashFlowFromContinuingInvestingActivities | -19.17K | 0.00 | 0.00 | -131.96K |
| NetPPEPurchaseAndSale | -19.17K | 0.00 | 0.00 | -131.96K |
| PurchaseOfPPE | -19.17K | 0.00 | 0.00 | -131.96K |
| OperatingCashFlow | -18.32M | -7.29M | -11.22M | -11.09M |
| CashFlowFromContinuingOperatingActivities | -18.32M | -7.29M | -11.22M | -11.09M |
| ChangeInWorkingCapital | -3.42M | 982.13K | -730.97K | 356.22K |
| ChangeInOtherWorkingCapital | 71.13K | 82.07K | -61.15K | |
| ChangeInOtherCurrentLiabilities | 0.00 | -16.75K | -50.59K | |
| ChangeInPayablesAndAccruedExpense | -3.51M | 911.62K | -1.22M | 916.15K |
| ChangeInAccruedExpense | -2.94M | 161.96K | -556.07K | 1.19M |
| ChangeInInterestPayable | 0.00 | 36.92K | 0.00 | |
| ChangeInPayable | -576.28K | 749.66K | -666.04K | -269.64K |
| ChangeInAccountPayable | -576.28K | 749.66K | -666.04K | -269.64K |
| ChangeInPrepaidAssets | 17.99K | -11.56K | 569.04K | -509.34K |
| OtherNonCashItems | 25.00K | 14.96K | 52.38K | |
| StockBasedCompensation | 168.85K | 155.72K | 301.12K | 470.88K |
| DepreciationAmortizationDepletion | 27.92K | 25.05K | 25.05K | 16.78K |
| DepreciationAndAmortization | 27.92K | 25.05K | 25.05K | 16.78K |
| Depreciation | 27.92K | 25.05K | 25.05K | 16.78K |
| OperatingGainsLosses | -81.44K | -8.33M | ||
| GainLossOnInvestmentSecurities | -81.44K | -8.33M | ||
| NetIncomeFromContinuingOperations | -15.04M | -120.25K | -10.83M | -11.99M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for REVB
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|